Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 80 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ondansetron placebo Clear all
Completed Not applicable Interventional

Ondansetron VS Doxylamine and Pyridoxine in Treating Nausea of Pregnancy

NCT01668069
View directory record Official record
Conditions
Vomiting of Pregnancy
Interventions
Ondansetron
Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 90 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 3 Interventional

Efficacy of Aprepitant (Emend®) in Children

NCT01661335
View directory record Official record
Conditions
Nausea, Vomiting, Childhood Cancer
Interventions
Ondansetron, dexamethasone, aprepitant, Ondansetron, Dexamethasone, placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
6 Months to 20 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 2 Interventional

Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

NCT00104403
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting
Interventions
GW679769, Dexamethasone, Ondansetron Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
47
States / cities
Birmingham, Alabama • Corona, California • Greenbrae, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 3 Interventional

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

NCT00006348
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ondansetron, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 3 Interventional Results available

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

NCT03578081
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
565
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Kingman, Arizona + 372 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Results available

ACL Repair and Multimodal Analgesia

NCT01868425
View directory record Official record
Conditions
Pain
Interventions
multimodal:acetaminophen, gabapentin, ketamine, bupivacaine, placebo pills and injectables
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 55 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

NCT01395901
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
Up to 16 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Florence, Alabama • Sheffield, Alabama • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 2 Interventional Results available

Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons

NCT01254877
View directory record Official record
Conditions
Alcohol Abuse, Alcohol Dependence
Interventions
Ondansetron, placebo ondansetron
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 3 Interventional Results available

Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens

NCT02635984
View directory record Official record
Conditions
Complications of Bone Marrow Transplant, Hematologic Neoplasms
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 2 Interventional

PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)

NCT01377662
View directory record Official record
Conditions
Methamphetamine Dependence, Cocaine Dependence
Interventions
OND-PR002 and MPh-IR, Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR
Drug · Other
Lead sponsor
Tong Lee
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 3 Interventional Results available

Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA

NCT02601027
View directory record Official record
Conditions
Breast - Female
Interventions
Transversus Abdominis Plane (TAP) block, Nimbus Infusion Pump IV Administration, Bupivacaine infusion, Acetominophen, Hydromorphone, Oxycodone, Ondansetron
Procedure · Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 2, 2026, 7:01 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers

NCT03809234
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Ondansetron 8mg with Saline & Tariquidar, Ondansetron 16mg with Saline & Tariquidar
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 3 Interventional Results available

Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

NCT02772965
View directory record Official record
Conditions
Pediatric Crohn's Disease
Interventions
Methotrexate, Sugar pill (placebo)
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Up to 20 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
32
States / cities
Birmingham, Alabama • Alto, California • New Haven, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Not applicable Interventional Results available

5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence

NCT01549652
View directory record Official record
Conditions
Opioid Withdrawal, Physical Dependence
Interventions
Ondansetron, Placebo, Morphine, Naloxone 0.4 mg/70 kg, Naloxone 0.8 mg/70 kg
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 2 Interventional

Ondansetron for the Treatment of Cocaine Dependence - 1

NCT00033085
View directory record Official record
Conditions
Cocaine-Related Disorders, Drug Administration Schedule
Interventions
Ondansetron
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery

NCT00659945
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant plus Ondansetron, Ondansetron plus placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tariquidar-ondansetron Combination in Neuropathic Pain

NCT04603066
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Ondansetron 16 mg with Tariquidar, Ondansetron 16 mg with Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Not applicable Interventional Results available

Prevention of Intraoperative Nausea and Vomiting During Cesarean Section

NCT01216410
View directory record Official record
Conditions
Cesarean Delivery
Interventions
Metoclopramide, Phenylephrine infusion, Combination Group
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 2, 2026, 7:01 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)

NCT07697625
View directory record Official record
Conditions
Healthy
Interventions
MK-4082, Diltiazem, Rescue medication
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 2, 2026, 7:01 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia

NCT02614586
View directory record Official record
Conditions
Schizophrenia
Interventions
TAK-058, Ondansetron, TAK-058 Placebo, Ondansetron Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 2 Interventional

Post-Operative Nausea And Vomiting Study In Female Patients

NCT00274690
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
11
States / cities
San Francisco, California • Melbourne, Florida • West Palm Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 4 Interventional Results available

Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy

NCT00878228
View directory record Official record
Conditions
Nausea and Vomiting, Postoperative
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

NCT01442376
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
Up to 16 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Little Rock, Arkansas • Duarte, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 2, 2026, 7:01 AM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder

NCT02354703
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 2, 2026, 7:01 AM EDT